§ 316.52. Availability for public disclosure of data and information in requests and applications.
234 words·~1 min read·
/us/cfr/t21/s§ 316.52·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)FDA will not publicly disclose the existence of a request for orphan-drug designation under section 526 of the act prior to final FDA action on the request unless the existence of the request has been previously publicly disclosed or acknowledged.
(b)Whether or not the existence of a pending request for designation has been publicly disclosed or acknowledged, no data or information in the request are available for public disclosure prior to final FDA action on the request.
(c)Upon final FDA action on a request for designation, FDA will determine the public availability of data and information in the request in accordance with part 20 and § 314.430 of this chapter and other applicable statutes and regulations.
(d)In accordance with § 316.28, FDA will make a cumulative list of all orphan drug designations available to the public and update such list monthly.
(e)FDA will not publicly disclose the existence of a pending marketing application for a designated orphan drug for the use for which the drug was designated unless the existence of the application has been previously publicly disclosed or acknowledged.
(f)FDA will determine the public availability of data and information contained in pending and approved marketing applications for a designated orphan drug for the use for which the drug was designated in accordance with part 20 and § 314.430 of this chapter and other applicable statutes and regulations.